Industry
Featured experience
Amgen $28.5 billion Horizon Therapeutics acquisition financing
We advised the lender parties on the financing
Forbion European Acquisition $138 million combination with enGene
We advised Forbion European Acquisition on its de-SPAC transaction
Bausch + Lomb $630 million IPO
We are advising Bausch Health on the separation of its eye health business into a new public company, Bausch + Lomb
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Metagenomi $93.75 million IPO
The shares are listed on the Nasdaq Global Market
Tenaya Therapeutics $50 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Gilead Sciences $4.3 billion acquisition of CymaBay Therapeutics
We are advising Gilead Sciences on the acquisition
Eli Lilly $6.5 billion notes offering
The investment-grade notes are due 2027, 2029, 2034, 2054 and 2064
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
Immunocore Holdings $402.5 million convertible notes offering
The 2.5% convertible notes are due 2030
Greenway Health $375 million refinancing
We advised the administrative agent, arrangers and bookrunners on the financing
Immatics $201 million follow-on offering
We advised Immatics on the offering of shares
IDEAYA Biosciences $350 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Alector $75 million stock offering
The common stock is listed on the Nasdaq Global Select Market